A detailed history of Geode Capital Management, LLC transactions in Kura Oncology, Inc. stock. As of the latest transaction made, Geode Capital Management, LLC holds 1,780,509 shares of KURA stock, worth $16 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,780,509
Previous 1,738,974 2.39%
Holding current value
$16 Million
Previous $35.8 Million 2.83%
% of portfolio
0.0%
Previous 0.0%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$18.57 - $23.23 $771,304 - $964,858
41,535 Added 2.39%
1,780,509 $34.8 Million
Q2 2024

Aug 09, 2024

BUY
$17.53 - $22.98 $555,701 - $728,466
31,700 Added 1.86%
1,738,974 $35.8 Million
Q1 2024

May 13, 2024

BUY
$13.42 - $23.53 $687,976 - $1.21 Million
51,265 Added 3.1%
1,707,274 $36.4 Million
Q4 2023

Feb 13, 2024

BUY
$7.58 - $14.38 $591,641 - $1.12 Million
78,053 Added 4.95%
1,656,009 $23.8 Million
Q3 2023

Nov 13, 2023

BUY
$8.44 - $11.86 $2.11 Million - $2.96 Million
249,840 Added 18.81%
1,577,956 $14.4 Million
Q2 2023

Aug 11, 2023

BUY
$9.62 - $13.99 $399,961 - $581,648
41,576 Added 3.23%
1,328,116 $14.1 Million
Q1 2023

May 15, 2023

BUY
$10.71 - $14.6 $611,648 - $833,806
57,110 Added 4.65%
1,286,540 $15.7 Million
Q4 2022

Feb 13, 2023

BUY
$11.23 - $16.9 $445,550 - $670,507
39,675 Added 3.33%
1,229,430 $15.3 Million
Q3 2022

Nov 14, 2022

SELL
$12.01 - $19.45 $174,805 - $283,094
-14,555 Reduced 1.21%
1,189,755 $16.3 Million
Q2 2022

Aug 12, 2022

BUY
$10.71 - $18.33 $1.03 Million - $1.77 Million
96,533 Added 8.71%
1,204,310 $22.1 Million
Q1 2022

May 13, 2022

SELL
$11.78 - $16.98 $1.13 Million - $1.63 Million
-96,049 Reduced 7.98%
1,107,777 $17.8 Million
Q4 2021

Feb 11, 2022

BUY
$12.22 - $19.57 $1.22 Million - $1.96 Million
100,066 Added 9.07%
1,203,826 $16.9 Million
Q3 2021

Nov 12, 2021

SELL
$15.42 - $21.72 $715,441 - $1.01 Million
-46,397 Reduced 4.03%
1,103,760 $20.7 Million
Q2 2021

Aug 13, 2021

BUY
$20.85 - $29.88 $1.31 Million - $1.87 Million
62,700 Added 5.77%
1,150,157 $24 Million
Q1 2021

May 12, 2021

BUY
$24.75 - $39.14 $2.28 Million - $3.6 Million
91,966 Added 9.24%
1,087,457 $30.7 Million
Q4 2020

Feb 12, 2021

BUY
$29.0 - $41.62 $4.67 Million - $6.7 Million
160,911 Added 19.28%
995,491 $32.5 Million
Q3 2020

Nov 13, 2020

BUY
$16.3 - $30.64 $1.53 Million - $2.87 Million
93,712 Added 12.65%
834,580 $25.6 Million
Q2 2020

Aug 13, 2020

BUY
$7.95 - $18.81 $1.27 Million - $3.01 Million
159,884 Added 27.52%
740,868 $12.1 Million
Q1 2020

May 14, 2020

BUY
$6.45 - $14.04 $392,430 - $854,221
60,842 Added 11.7%
580,984 $5.78 Million
Q4 2019

Feb 13, 2020

BUY
$12.97 - $15.94 $273,796 - $336,493
21,110 Added 4.23%
520,142 $7.15 Million
Q3 2019

Nov 12, 2019

BUY
$14.75 - $20.87 $851,104 - $1.2 Million
57,702 Added 13.07%
499,032 $7.57 Million
Q2 2019

Aug 14, 2019

BUY
$14.71 - $19.79 $993,601 - $1.34 Million
67,546 Added 18.07%
441,330 $8.69 Million
Q1 2019

May 14, 2019

BUY
$13.73 - $16.87 $271,497 - $333,587
19,774 Added 5.59%
373,784 $6.2 Million
Q4 2018

Feb 13, 2019

BUY
$10.6 - $17.49 $457,973 - $755,655
43,205 Added 13.9%
354,010 $4.97 Million
Q3 2018

Nov 13, 2018

BUY
$16.65 - $21.85 $595,970 - $782,098
35,794 Added 13.02%
310,805 $5.44 Million
Q2 2018

Aug 14, 2018

BUY
$14.8 - $18.8 $616,864 - $783,584
41,680 Added 17.86%
275,011 $5.01 Million
Q1 2018

May 15, 2018

BUY
$14.5 - $23.4 $963,046 - $1.55 Million
66,417 Added 39.79%
233,331 $4.37 Million
Q4 2017

Feb 13, 2018

BUY
$13.5 - $16.65 $43,942 - $54,195
3,255 Added 1.99%
166,914 $2.55 Million
Q3 2017

Nov 14, 2017

BUY
$6.05 - $14.95 $548,977 - $1.36 Million
90,740 Added 124.44%
163,659 $2.45 Million
Q2 2017

Aug 14, 2017

BUY
N/A
72,919
72,919 $678,000

Others Institutions Holding KURA

About Kura Oncology, Inc.


  • Ticker KURA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 66,893,000
  • Market Cap $603M
  • Description
  • Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A p...
More about KURA
Track This Portfolio

Track Geode Capital Management, LLC Portfolio

Follow Geode Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Geode Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Geode Capital Management, LLC with notifications on news.